|
Avaliação DCF Moderna, Inc. (mRNA)
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Moderna, Inc. (MRNA) Bundle
Otimize sua análise de avaliação Moderna, Inc. (mRNA) usando nossa calculadora DCF de ponta! Este modelo do Excel é pré -carregado com dados reais de mRNA, permitindo que você ajuste as previsões e suposições para determinar com precisão o valor intrínseco da Moderna, Inc. (mRNA).
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 274.5 | 17,736.0 | 19,263.0 | 6,848.0 | 3,236.0 | 3,166.5 | 3,098.6 | 3,032.1 | 2,967.0 | 2,903.3 |
| Revenue Growth, % | 0 | 6361.44 | 8.61 | -64.45 | -52.75 | -2.15 | -2.15 | -2.15 | -2.15 | -2.15 |
| EBITDA | -732.0 | 13,528.0 | 9,768.0 | -3,283.0 | -3,394.0 | -766.0 | -749.6 | -733.5 | -717.8 | -702.4 |
| EBITDA, % | -266.68 | 76.27 | 50.71 | -47.94 | -104.88 | -24.19 | -24.19 | -24.19 | -24.19 | -24.19 |
| Depreciation | 31.3 | 232.0 | 348.0 | 621.0 | 189.0 | 186.2 | 182.2 | 178.3 | 174.5 | 170.8 |
| Depreciation, % | 11.39 | 1.31 | 1.81 | 9.07 | 5.84 | 5.88 | 5.88 | 5.88 | 5.88 | 5.88 |
| EBIT | -763.3 | 13,296.0 | 9,420.0 | -3,904.0 | -3,583.0 | -843.2 | -825.1 | -807.4 | -790.1 | -773.1 |
| EBIT, % | -278.06 | 74.97 | 48.9 | -57.01 | -110.72 | -26.63 | -26.63 | -26.63 | -26.63 | -26.63 |
| Total Cash | 4,608.0 | 10,727.0 | 9,902.0 | 8,604.0 | 1,927.0 | 2,352.3 | 2,301.8 | 2,252.4 | 2,204.1 | 2,156.8 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 1,408.0 | 3,175.0 | 1,385.0 | 892.0 | 358.0 | 944.8 | 924.5 | 904.6 | 885.2 | 866.2 |
| Account Receivables, % | 512.95 | 17.9 | 7.19 | 13.03 | 11.06 | 29.84 | 29.84 | 29.84 | 29.84 | 29.84 |
| Inventories | 47.0 | 1,441.0 | 949.0 | 202.0 | 117.0 | 232.7 | 227.7 | 222.8 | 218.0 | 213.3 |
| Inventories, % | 17.12 | 8.12 | 4.93 | 2.95 | 3.62 | 7.35 | 7.35 | 7.35 | 7.35 | 7.35 |
| Accounts Payable | 18.0 | 302.0 | 487.0 | 520.0 | 405.0 | 195.7 | 191.5 | 187.4 | 183.3 | 179.4 |
| Accounts Payable, % | 6.56 | 1.7 | 2.53 | 7.59 | 12.52 | 6.18 | 6.18 | 6.18 | 6.18 | 6.18 |
| Capital Expenditure | -67.4 | -284.0 | -400.0 | -707.0 | -1,051.0 | -450.0 | -440.3 | -430.9 | -421.6 | -412.6 |
| Capital Expenditure, % | -24.57 | -1.6 | -2.08 | -10.32 | -32.48 | -14.21 | -14.21 | -14.21 | -14.21 | -14.21 |
| Tax Rate, % | 1.28 | 1.28 | 1.28 | 1.28 | 1.28 | 1.28 | 1.28 | 1.28 | 1.28 | 1.28 |
| EBITAT | -765.9 | 12,212.1 | 8,226.6 | -4,668.6 | -3,537.3 | -805.9 | -788.6 | -771.7 | -755.1 | -738.9 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -2,239.1 | 9,283.1 | 10,641.6 | -3,481.6 | -3,895.3 | -1,981.4 | -1,025.6 | -1,003.6 | -982.1 | -961.0 |
| WACC, % | 11.09 | 11.07 | 11.06 | 11.09 | 11.09 | 11.08 | 11.08 | 11.08 | 11.08 | 11.08 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -4,560.6 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | -999 | |||||||||
| Terminal Value | -14,117 | |||||||||
| Present Terminal Value | -8,348 | |||||||||
| Enterprise Value | -12,909 | |||||||||
| Net Debt | -1,217 | |||||||||
| Equity Value | -11,692 | |||||||||
| Diluted Shares Outstanding, MM | 384 | |||||||||
| Equity Value Per Share | -30.45 |
What You Will Get
- Real Moderna Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures.
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Moderna’s fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections.
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility.
Key Features
- Real-Life MRNA Data: Pre-filled with Moderna’s historical financials and forward-looking projections.
- Fully Customizable Inputs: Adjust revenue growth, margins, WACC, tax rates, and capital expenditures.
- Dynamic Valuation Model: Automatic updates to Net Present Value (NPV) and intrinsic value based on your inputs.
- Scenario Testing: Create multiple forecast scenarios to analyze different valuation outcomes.
- User-Friendly Design: Simple, structured, and designed for professionals and beginners alike.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Moderna data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Moderna’s intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for Moderna, Inc. (MRNA)?
- Accurate Data: Access to real Moderna financials ensures dependable valuation outcomes.
- Customizable: Tailor essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Pre-configured calculations save you the effort of starting from the ground up.
- Professional-Grade Tool: Crafted for investors, analysts, and consultants in the biotech sector.
- User-Friendly: An intuitive design and clear step-by-step guidance make it accessible for all users.
Who Should Use This Product?
- Healthcare Students: Understand vaccine development processes and analyze real-world data.
- Researchers: Integrate advanced models into studies related to biotechnology and pharmaceuticals.
- Investors: Evaluate your investment strategies and assess valuation scenarios for Moderna, Inc. (MRNA).
- Market Analysts: Enhance your analysis with a customizable DCF model tailored for biotech companies.
- Entrepreneurs: Learn from the valuation techniques used for leading biotech firms like Moderna, Inc. (MRNA).
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Moderna historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Moderna, Inc. (MRNA).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.